ID   182-D1106-362
AC   CVCL_A6LD
SY   175D10
DR   Wikidata; Q107113149
RX   Patent=US10314890;
RX   Patent=US10738108;
RX   PubMed=19047087;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2810.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized IMAB362 (claudiximab; zolbetuximab) therapeutic antibody.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (Note=Isoform A2 = CLDN18.2).
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3412 ! P3X63Ag8U.1
CA   Hybridoma
DT   Created: 20-05-21; Last updated: 10-09-24; Version: 6
//
RX   PubMed=19047087; DOI=10.1158/1078-0432.CCR-08-1547;
RA   Sahin, Ugur
RA   Koslowski, Michael
RA   Dhaene, Karl
RA   Usener, Dirk
RA   Brandenburg, Gunda
RA   Seitz, Guido
RA   Huber, Christoph
RA   Tureci, Ozlem
RT   "Claudin-18 splice variant 2 is a pan-cancer target suitable for
RT   therapeutic antibody development.";
RL   Clin. Cancer Res. 14:7624-7634(2008).
//
RX   Patent=US10314890;
RA   Sahin, Ugur
RA   Tureci, Ozlem
RA   Mitnacht-Kraus, Rita
RA   Woll, Stefan
RA   Jacobs, Stefan
RA   Heinz, Cornelia
RT   "Combination therapy involving antibodies against claudin 18.2 for
RT   treatment of cancer.";
RL   Patent number US10314890, 11-Jun-2019.
//
RX   Patent=US10738108;
RA   Sahin, Ugur
RA   Tureci, Ozlem
RA   Usener, Dirk
RA   Fritz, Stefan
RA   Uherek, Christoph
RA   Brandenburg, Gunda
RA   Geppert, Harald-Gerhard
RA   Schroder, Anja Kristina
RA   Thiel, Phillippe
RT   "Monoclonal antibodies against claudin-18 for treatment of cancer.";
RL   Patent number US10738108, 11-Aug-2020.
//